Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients

BACKGROUND: The main pathophysiological basis of coronavirus disease 2019 (COVID-19) causing respiratory failure is a cytokine storm and interleukin-6 (IL-6) is an important component of the COVID-19 cytokine storm. As a specific antagonist of IL-6, tocilizumab may block the cytokine storm of COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Jia, Xie, Ming-Hui, Yang, Jing, Chao, Sheng-Wu, Xu, Er-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479568/
https://www.ncbi.nlm.nih.gov/pubmed/32953852
http://dx.doi.org/10.12998/wjcc.v8.i17.3763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479568/
https://www.ncbi.nlm.nih.gov/pubmed/32953852
http://dx.doi.org/10.12998/wjcc.v8.i17.3763

Ejemplares similares